Figure 12.

BCL-XL as a potential biomarker in Leukemia. ONCOMINE analysis of BCL-XL was revised and compared to clinical features of patients with Leukemia. (A) The dataset from the analysis conducted by Heuser [88] of BCL-XL expression was performed. A discrete increase was observed in dead patients. (B) In Bullinger’ leukemia dataset [89], a lower expression of BCL-xL was observed in patients with complete response vs. refractory disease. (C) Data from the study by Heuser is shown on responder vs. failure response patients (* p < 0.05). (D) In the same dataset lower expression of BCL-XL was related with a favorable outcome (* p < 0.05). (E) In the same dataset, the analysis of BCL-XL as a function of BCR-ABL is shown. (F) The expression of BCL-XL is shown in relapse patient vs. complete response patients (** p < 0.001).